- Home
- GDEN vs BCAX Comparison
GDEN vs BCAX Comparison
Compare GDEN & BCAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDEN
- BCAX
- Stock Information
- Founded
- GDEN 1998
- BCAX 2018
- Country
- GDEN United States
- BCAX United States
- Employees
- GDEN N/A
- BCAX N/A
- Industry
- GDEN Services-Misc. Amusement & Recreation
- BCAX
- Sector
- GDEN Consumer Discretionary
- BCAX
- Exchange
- GDEN Nasdaq
- BCAX NYSE
- Market Cap
- GDEN 705.7M
- BCAX 670.9M
- IPO Year
- GDEN 1999
- BCAX 2024
- Fundamental
- Price
- GDEN $27.32
- BCAX $12.97
- Analyst Decision
- GDEN Strong Buy
- BCAX Buy
- Analyst Count
- GDEN 7
- BCAX 7
- Target Price
- GDEN $36.86
- BCAX $29.67
- AVG Volume (30 Days)
- GDEN 152.9K
- BCAX 586.0K
- Earning Date
- GDEN 05-08-2025
- BCAX 05-20-2025
- Dividend Yield
- GDEN 3.85%
- BCAX N/A
- EPS Growth
- GDEN N/A
- BCAX N/A
- EPS
- GDEN 0.39
- BCAX N/A
- Revenue
- GDEN $653,614,000.00
- BCAX N/A
- Revenue This Year
- GDEN $2.32
- BCAX N/A
- Revenue Next Year
- GDEN $2.80
- BCAX N/A
- P/E Ratio
- GDEN $66.78
- BCAX N/A
- Revenue Growth
- GDEN N/A
- BCAX N/A
- 52 Week Low
- GDEN $22.66
- BCAX $8.91
- 52 Week High
- GDEN $35.49
- BCAX $28.09
- Technical
- Relative Strength Index (RSI)
- GDEN 58.80
- BCAX N/A
- Support Level
- GDEN $25.28
- BCAX N/A
- Resistance Level
- GDEN $26.67
- BCAX N/A
- Average True Range (ATR)
- GDEN 0.85
- BCAX 0.00
- MACD
- GDEN 0.20
- BCAX 0.00
- Stochastic Oscillator
- GDEN 83.40
- BCAX 0.00
About GDEN Golden Entertainment Inc.
Golden Entertainment Inc is a U.S. based company that focuses on distributed gaming, casino, and resort operations. Its reportable segments are Nevada Casino Resorts, Nevada Locals Casinos, Nevada Taverns, and Distributed Gaming. The majority of the revenue for the company is generated from its Nevada Casino Resorts segment which is comprised of destination casino resort properties offering a variety of food and beverage outlets, entertainment venues, and other amenities.
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.